Cobenfy Sales Miss Estimates in Third Quarter

Bristol Myers Squibb reports $57 million in quarterly sales for the drug amid prescription and side effect challenges.

Updated on Oct. 29, 2026 in Cancer

Cobenfy Sales Miss Estimates in Third Quarter

Live Poll

Do you trust that pharmaceutical companies manage the launch and rollout of new medications effectively?

In the third quarter of 2026, Bristol Myers Squibb reported $57 million in sales for Cobenfy, missing analyst expectations by $11 million. While total company revenue rose by 7% year-over-year, sales growth for the drug was hindered by gastrointestinal side effects and prescribing behaviors.

Why it matters

Sales performance for Cobenfy has faced headwinds as physicians work to manage nausea and vomiting during drug initiation. These challenges, combined with inventory issues, led analysts to reduce revenue projections for the product through 2030 by roughly 40%.

Cobenfy recorded $57 million in sales during the third quarter, while the company maintains a broader 2026 revenue guidance of $49.75 billion to $50.25 billion. Clinicians currently titrate patients to a 125 mg dose to mitigate gastrointestinal side effects.

The players

Bristol Myers Squibb

This global biopharmaceutical company focuses on developing innovative medicines for serious diseases including cancer and immunology.

The details

Bristol Myers Squibb utilizes antiemetics to support patients during drug initiation to counter nausea. Despite the sales miss for Cobenfy, the company's legacy portfolio, including Revlimid with $303 million in sales, drove overall revenue growth.

2024: Bristol Myers Squibb acquired Cobenfy for $14 billion.
2025: Cobenfy generated $155 million in total annual sales.
December 2025: BMS delayed Adept-2 trial readouts due to irregularities.
Summer 2026: BMS delayed Adept trial readouts due to enrollment speed.
Around the new year: Adept trial results are scheduled to be released.

Health Landscape

The drug's commercial trajectory follows the clinical timeline of the Adept trial program for Cobenfy. This update marks a point of transition as the company balances current market hurdles with upcoming data readouts.

Patients prescribed Cobenfy may experience adjustments in their dosing schedule as physicians continue to titrate the 125 mg dose to manage gastrointestinal side effects. Those initiating treatment should discuss the use of antiemetics with their healthcare provider to mitigate potential nausea.

The takeaway

The gap between sales and estimates underscores the practical difficulties of managing new drug side effects in a clinical setting. Monitoring the upcoming Adept trial results will be essential for understanding the product's long-term market potential.

What happens next

Clinical trial results for Cobenfy in Alzheimer's disease psychosis are expected around the new year, alongside scheduled readouts for the drug milvexian.